Skip to content
HowShorted

Fate Therapeutics, Inc. short interest in 2018

In 2018, Fate Therapeutics, Inc.'s disclosed short interest ran from 2.96% of shares outstanding on 12 Jan 2018 to 13.14% on 31 Dec 2018, a change of +10.18 percentage points. The year's high was 13.14% on 31 Dec 2018 and its low 2.96% on 12 Jan 2018, averaging 8.78% across 24 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 22.37 days on 13 Jul 2018. Full history: Fate Therapeutics, Inc..

Cite this page
Plain
Wikipedia
BibTeX

By year: 2018 · 2019 · 2020 · 2021 · 2022 · 2023 · 2024 · 2025 · 2026

Aggregate net short position time series for Fate Therapeutics, Inc. in 2018

2018 in figures

Start of year
2.96% (12 Jan 2018)
End of year
13.14% (31 Dec 2018)
Change
+10.18 pp
High
13.14% (31 Dec 2018)
Low
2.96% (12 Jan 2018)
Average
8.78%
Highest days to cover
22.37 (13 Jul 2018)
SEC filings marked
8

Every report in 2018

Fate Therapeutics, Inc. short interest in 2018
SettlementShort interestDays to coverFilings since previous
12 Jan 20182.96%2.20
31 Jan 20183.30%2.03
15 Feb 20184.29%3.19
28 Feb 20185.52%2.21
15 Mar 20186.45%3.0510-K filed, results (8-K)
29 Mar 20186.56%5.02
13 Apr 20188.23%7.26
30 Apr 20188.49%9.90
15 May 20188.41%7.1310-Q filed, results (8-K)
31 May 20188.32%10.34
15 Jun 20187.96%4.06
29 Jun 201810.11%6.82
13 Jul 20189.88%22.37
31 Jul 20189.31%10.98
15 Aug 20189.72%10.5110-Q filed, results (8-K)
31 Aug 20189.34%13.59
14 Sep 20189.27%14.61
28 Sep 201811.29%4.90
15 Oct 201811.97%9.38
31 Oct 201810.87%10.76
15 Nov 201811.06%8.3810-Q filed, results (8-K)
30 Nov 201812.43%14.50
14 Dec 201811.74%6.44
31 Dec 201813.14%7.32

See also: Fate Therapeutics, Inc.'s full history · most shorted US stocks of 2018 · today's US league.

About this data

US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.